News Safety restrictions spell the end for Servier osteoporosis d... Sales of Protelos hit by safety restrictions.
News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News Pfizer's fast-tracked leukaemia candidate could rival CAR-Ts Antibody-drug conjugate with FDA gets six-month review.
News Amgen/UCB reveal new osteoporosis drug data But romosozumab missed secondary endpoint of non-vertebral fractures
Articles Stop being control freaks: pharma’s challenge in involving p... Lode Dewulf, chief patient affairs officer at UCB, tells Paul Tunnah how patient-centricity is evolving, and describes how pharma still needs to adapt.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
